BCIM
MYGN icon

British Columbia Investment Management’s Myriad Genetics MYGN Stock Holding History

British Columbia Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-22,400
Closed -$840K – 699
2015
Q3 		$840K Hold
22,400
– – 0.01% 649
2015
Q2 		$761K Buy
22,400
+2,300
+11% +$78.2K 0.01% 688
2015
Q1 		$712K Buy
+20,100
New +$719K 0.01% 671

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

British Columbia Investment Management's MYGN Position: Q4 2015 in Review

British Columbia Investment Management sold out of Myriad Genetics (MYGN) in Q4 2015, closing a stake of 22,400 shares — an estimated $840K sold.

British Columbia Investment Management first reported a position in MYGN in Q1 2015 and held it in 3 quarters. The position peaked at $840K in Q3 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q4 2015.

  • British Columbia Investment Management reported no remaining Myriad Genetics position as of Q4 2015 after selling out during the quarter.
  • British Columbia Investment Management sold 22,400 Myriad Genetics shares in Q4 2015, an estimated $840K.
  • British Columbia Investment Management first reported a position in Myriad Genetics in Q1 2015 and held it in 3 quarters.
  • British Columbia Investment Management's Myriad Genetics position peaked at $840K in Q3 2015.
  • 233 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2015.

Based on British Columbia Investment Management's 13F filing for Q4 2015, filed 25 Jan 2016.